Epperly Melissa B,'s Form 4 filing
Zentalis Pharmaceuticals, Inc. (ZNTL) · filed Apr 5, 2022
- Accession no.
- 0001725160-22-000069
- Filed
- Apr 5, 2022
- Trade date
- Apr 4, 2022
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 5 non-derivative transactions. Open-market sales total $855.6K. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Epperly Melissa B,CIK 0001807359 | Officer (Chief Financial Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Apr 4, 2022 | Common Stock | SSaleDisposed | −8,094 | $48.75F2 | −$394,582.5 | 256,400 | Direct | |
| Apr 4, 2022 | Common Stock | SSaleDisposed | −1,303 | $49.90F3 | −$65,019.7 | 255,097 | Direct | |
| Apr 4, 2022 | Common Stock | SSaleDisposed | −2,818 | $50.70F4 | −$142,872.6 | 252,279 | Direct | |
| Apr 4, 2022 | Common Stock | SSaleDisposed | −4,512 | $51.99F5 | −$234,578.88 | 247,767 | Direct | |
| Apr 4, 2022 | Common Stock | SSaleDisposed | −353 | $52.44F6 | −$18,511.32 | 247,414 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $48.35 to $49.33. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Referenced by the price of 1 transaction in Table I.
- F3
The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $49.38 to $50.37. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Referenced by the price of 1 transaction in Table I.
- F4
The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $50.38 to $51.32. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Referenced by the price of 1 transaction in Table I.
- F5
The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $51.41 to $52.40. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Referenced by the price of 1 transaction in Table I.
- F6
The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $52.41 to $52.54. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Referenced by the price of 1 transaction in Table I.